During the past 12 months, Relmada Therapeutics's average Book Value per Share Growth Rate was -39.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Relmada Therapeutics was 563.80% per year. The lowest was -30.60% per year. And the median was 81.50% per year.
Competitive Comparison of Relmada Therapeutics's 3-Year Book Growth Rate
For the Biotechnology subindustry, Relmada Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relmada Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's 3-Year Book Growth Rate falls into.
Relmada Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Relmada Therapeutics (NAS:RLMD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Relmada Therapeutics 3-Year Book Growth Rate Related Terms
Thank you for viewing the detailed overview of Relmada Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Relmada Therapeutics (Relmada Therapeutics) Business Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLMD has been successfully added to your